Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CASI PharmaceuticalsCASIF -4.59%26 3-Year FCF Growth Rate is 16.90% as of Dec. 2025, which is at its 10-year median of 16.90. GuruFocus rates CASIF with a GF Score™ of 26/100 and a GF Value™ of $1.07 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,103 Biotechnology companies, CASI Pharmaceuticals ranks worse than 53.49% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 16.90% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 20.60% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 1.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of CASI Pharmaceuticals was 54.80% per year. The lowest was -123.60% per year. And the median was 16.90% per year.
CASI Pharmaceuticals (OTCPK:CASIF) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
CASI Pharmaceuticals 3-Year FCF Growth Rate Related Terms
CASIF vs CMND, VBIO, BIXT: 3-Year FCF Growth Rate Comparison
For the Biotechnology subindustry, CASI Pharmaceuticals's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals 3-Year FCF Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's 3-Year FCF Growth Rate falls into.
CASI Pharmaceuticals 3-Year FCF Growth Rate Calculation
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 16.90% mean?
CASI Pharmaceuticals (CASIF) has a 3-Year FCF Growth Rate of 16.90% as of Dec. 2025. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for CASI Pharmaceuticals and its competitors. This is near median its historical median of 16.90. According to the industry distribution chart, CASI Pharmaceuticals ranks #590 out of 1103 companies in the Biotechnology industry, placing it in the top 53.5%.
Is CASI Pharmaceuticals' 3-Year FCF Growth Rate too high?
CASI Pharmaceuticals' current 3-Year FCF Growth Rate of 16.90% is near median its 10-year median of 16.90. The Biotechnology industry median 3-Year FCF Growth Rate is 19.40. CASI Pharmaceuticals' value of 16.90% is 12.9% below this industry median. Based on the distribution chart, CASI Pharmaceuticals ranks #590 out of 1103 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CASI Pharmaceuticals has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' 3-Year FCF Growth Rate compare to CMND and VBIO?
According to the Biotechnology industry distribution chart, CASI Pharmaceuticals ranks #590 out of 1103 companies for 3-Year FCF Growth Rate. This places CASI Pharmaceuticals in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 19.40. CASI Pharmaceuticals' value of 16.90% is 12.9% below this benchmark. While the company's 10-year median is 16.90 vs. the industry median of 19.40, CASI Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Biotechnology company?
The median 3-Year FCF Growth Rate among Biotechnology companies is 19.40, based on 1,103 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CASI Pharmaceuticals's current 3-Year FCF Growth Rate of 16.90% is 12.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for CASI Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year FCF Growth Rate is 19.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CASI Pharmaceuticals's current 3-Year FCF Growth Rate is 16.90%, which is near median its own 10-year median of 16.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CASI Pharmaceuticals (CASIF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.07, compared to a current price of $0.13 — trading 88% below its estimated fair value. The current 3-Year FCF Growth Rate is 16.90%, which is near median its 10-year median of 16.90 and 12.9% below the Biotechnology industry median of 19.40. CASI Pharmaceuticals' overall GF Score™ is 26/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For CASI Pharmaceuticals (CASIF), the current 3-Year FCF Growth Rate is 16.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CASI Pharmaceuticals (CASIF) Overvalued in 2026?
Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.13 is trading 88% below its estimated GF Value™ of $1.07.
GuruFocus considers CASI Pharmaceuticals to be Possible Value Trap.
Key valuation signals for CASIF:
3-Year FCF Growth Rate: 16.90% (near median its 10-year median of 16.90)
GF Value™: $1.07 vs. price of $0.13 (88% below fair value)
Industry Position: 12.9% below the Biotechnology median (#590 of 1103)
No single metric tells the full story. See the CASIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
26GF Score
Get the complete analysis for CASIF
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASIF has been successfully added to your 
